Cargando…

MicroRNA-181a-3p as a Diagnostic and Prognostic Biomarker for Acute Myeloid Leukemia

BACKGROUND: Micro (mi) RNAs play an important role in the pathogenesis and development of acute myeloid leukemia (AML), and their abnormal expression may be sufficient to predict the prognosis and outcomes in AML patients. We evaluated the clinical diagnostic value of miRNA-181a-3p in predicting pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiang, Ping, Pan, Qing, Fang, Chao, Fozza, Claudio, Song, Kaidi, Dai, Yuanyuan, Chang, Wenjiao, Chen, Wei, Yao, Wan, Zhu, Weibo, Liu, Xin, Ma, Xiaoling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059742/
https://www.ncbi.nlm.nih.gov/pubmed/32180907
http://dx.doi.org/10.4084/MJHID.2020.012
_version_ 1783504111193292800
author Qiang, Ping
Pan, Qing
Fang, Chao
Fozza, Claudio
Song, Kaidi
Dai, Yuanyuan
Chang, Wenjiao
Chen, Wei
Yao, Wan
Zhu, Weibo
Liu, Xin
Ma, Xiaoling
author_facet Qiang, Ping
Pan, Qing
Fang, Chao
Fozza, Claudio
Song, Kaidi
Dai, Yuanyuan
Chang, Wenjiao
Chen, Wei
Yao, Wan
Zhu, Weibo
Liu, Xin
Ma, Xiaoling
author_sort Qiang, Ping
collection PubMed
description BACKGROUND: Micro (mi) RNAs play an important role in the pathogenesis and development of acute myeloid leukemia (AML), and their abnormal expression may be sufficient to predict the prognosis and outcomes in AML patients. We evaluated the clinical diagnostic value of miRNA-181a-3p in predicting prognosis and outcomes in patients with AML. METHODS: A total of 119 newly diagnosed adult patients with AML and 60 healthy controls were recruited. Blood specimens were obtained from all AML patients at diagnosis, and 10 blood specimens were obtained on day 28 after induction chemotherapy. The controls also provided blood samples. Relative gene expression was quantified by PCR and determined using the comparative Ct method. Publicly available clinical data and gene expressions for 188 patients with AML were downloaded from TCGA data portal. RESULTS: Compared with healthy controls, the expression of miRNA-181a-3p was significantly increased in patients with AML. MiR-181a-3p expression could be used to discriminate AML patients from controls, with up-regulated expression correlating with favorable prognosis. Moreover, miRNA-181a-3p expression was significantly decreased in patients who achieved a complete response after induction chemotherapy. The multivariate Cox analysis highlighted the prognostic value of miR-181a-3p for patients with AML. Finally, we found that miR-181a-3p expression was negatively correlated with the expression of the NF-κB essential modulator (NEMO/IKBKG). CONCLUSIONS: MiR-181a-3p may be clinically useful as a disease marker for AML, and enhanced the prediction of patient outcomes to chemotherapy.
format Online
Article
Text
id pubmed-7059742
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Università Cattolica del Sacro Cuore
record_format MEDLINE/PubMed
spelling pubmed-70597422020-03-16 MicroRNA-181a-3p as a Diagnostic and Prognostic Biomarker for Acute Myeloid Leukemia Qiang, Ping Pan, Qing Fang, Chao Fozza, Claudio Song, Kaidi Dai, Yuanyuan Chang, Wenjiao Chen, Wei Yao, Wan Zhu, Weibo Liu, Xin Ma, Xiaoling Mediterr J Hematol Infect Dis Original Article BACKGROUND: Micro (mi) RNAs play an important role in the pathogenesis and development of acute myeloid leukemia (AML), and their abnormal expression may be sufficient to predict the prognosis and outcomes in AML patients. We evaluated the clinical diagnostic value of miRNA-181a-3p in predicting prognosis and outcomes in patients with AML. METHODS: A total of 119 newly diagnosed adult patients with AML and 60 healthy controls were recruited. Blood specimens were obtained from all AML patients at diagnosis, and 10 blood specimens were obtained on day 28 after induction chemotherapy. The controls also provided blood samples. Relative gene expression was quantified by PCR and determined using the comparative Ct method. Publicly available clinical data and gene expressions for 188 patients with AML were downloaded from TCGA data portal. RESULTS: Compared with healthy controls, the expression of miRNA-181a-3p was significantly increased in patients with AML. MiR-181a-3p expression could be used to discriminate AML patients from controls, with up-regulated expression correlating with favorable prognosis. Moreover, miRNA-181a-3p expression was significantly decreased in patients who achieved a complete response after induction chemotherapy. The multivariate Cox analysis highlighted the prognostic value of miR-181a-3p for patients with AML. Finally, we found that miR-181a-3p expression was negatively correlated with the expression of the NF-κB essential modulator (NEMO/IKBKG). CONCLUSIONS: MiR-181a-3p may be clinically useful as a disease marker for AML, and enhanced the prediction of patient outcomes to chemotherapy. Università Cattolica del Sacro Cuore 2020-03-01 /pmc/articles/PMC7059742/ /pubmed/32180907 http://dx.doi.org/10.4084/MJHID.2020.012 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Qiang, Ping
Pan, Qing
Fang, Chao
Fozza, Claudio
Song, Kaidi
Dai, Yuanyuan
Chang, Wenjiao
Chen, Wei
Yao, Wan
Zhu, Weibo
Liu, Xin
Ma, Xiaoling
MicroRNA-181a-3p as a Diagnostic and Prognostic Biomarker for Acute Myeloid Leukemia
title MicroRNA-181a-3p as a Diagnostic and Prognostic Biomarker for Acute Myeloid Leukemia
title_full MicroRNA-181a-3p as a Diagnostic and Prognostic Biomarker for Acute Myeloid Leukemia
title_fullStr MicroRNA-181a-3p as a Diagnostic and Prognostic Biomarker for Acute Myeloid Leukemia
title_full_unstemmed MicroRNA-181a-3p as a Diagnostic and Prognostic Biomarker for Acute Myeloid Leukemia
title_short MicroRNA-181a-3p as a Diagnostic and Prognostic Biomarker for Acute Myeloid Leukemia
title_sort microrna-181a-3p as a diagnostic and prognostic biomarker for acute myeloid leukemia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059742/
https://www.ncbi.nlm.nih.gov/pubmed/32180907
http://dx.doi.org/10.4084/MJHID.2020.012
work_keys_str_mv AT qiangping microrna181a3pasadiagnosticandprognosticbiomarkerforacutemyeloidleukemia
AT panqing microrna181a3pasadiagnosticandprognosticbiomarkerforacutemyeloidleukemia
AT fangchao microrna181a3pasadiagnosticandprognosticbiomarkerforacutemyeloidleukemia
AT fozzaclaudio microrna181a3pasadiagnosticandprognosticbiomarkerforacutemyeloidleukemia
AT songkaidi microrna181a3pasadiagnosticandprognosticbiomarkerforacutemyeloidleukemia
AT daiyuanyuan microrna181a3pasadiagnosticandprognosticbiomarkerforacutemyeloidleukemia
AT changwenjiao microrna181a3pasadiagnosticandprognosticbiomarkerforacutemyeloidleukemia
AT chenwei microrna181a3pasadiagnosticandprognosticbiomarkerforacutemyeloidleukemia
AT yaowan microrna181a3pasadiagnosticandprognosticbiomarkerforacutemyeloidleukemia
AT zhuweibo microrna181a3pasadiagnosticandprognosticbiomarkerforacutemyeloidleukemia
AT liuxin microrna181a3pasadiagnosticandprognosticbiomarkerforacutemyeloidleukemia
AT maxiaoling microrna181a3pasadiagnosticandprognosticbiomarkerforacutemyeloidleukemia